ANTERIS TECHNOLOGIES GLOBAL CORP (AVR)
Health Care · Transcatheter Heart Valve Replacement Devices · NASDAQ
A pre-revenue structural heart company pioneering a biomimetic, single-piece aortic valve designed to replicate healthy valve hemodynamics and durability in TAVR-eligible patients with aortic stenosis.
What ANTERIS TECHNOLOGIES GLOBAL CORP does
Anteris Technologies Global Corp is a structural heart company developing transcatheter aortic valve replacement (TAVR) therapies for aortic stenosis. The company's lead product, the DurAVR® THV System, is a single-piece biomimetic valve utilizing proprietary ADAPT® tissue-enhancing technology designed to mimic the performance of a healthy human aortic valve and deployed via the ComASUR® Delivery System. As of December 2025, over 130 patients have received DurAVR® implants, with the company conducting the PARADIGM Trial, a pivotal randomized controlled study comparing DurAVR® against commercially available TAVR alternatives.
Themes: Transcatheter aortic valve replacement (TAVR), Structural heart disease, Aortic stenosis treatment, Minimally-invasive cardiac interventions, Biomimetic medical devices, Tissue-engineered heart valves
Fundamentals
- Price$8.98 as of 2026-08-21 close
- Market cap$875M as of 2026-08-21
- 1-year return+135.1% 2025-08-21 close $3.82 → 2026-08-21 close $8.98
- P/En/a negative earnings
- Net margin-5148.8% as of 2026-08-24
- Gross margin+74.3% as of 2026-08-24
- ROE-64.7% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)-0.5% as of 2026-08-24
- Beta1.88 as of 2026-08-24
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How AVR compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ANTERIS TECHNOLOGIES GLOBAL CORP looks technically
ANTERIS TECHNOLOGIES GLOBAL CORP (AVR) is trading 39.4% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 167 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 51, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago. It is 18.8% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 39.4% above its 200-day average, the long-term trend line — a longer-term uptrend | +39.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $9.11 | $9.11 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $6.44 | $6.44 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 21 calendar days ago — the swings before that are what the structure reading is measured on | 21 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five; the labelling fails if price closes below 7.725. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 5 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 167 trading days ago — a "golden cross", a bullish long-term signal | 167 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend) | 21.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 51, neither overbought (above 70) nor oversold (below 30) | 51.0 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($7.95 to $10.09) — its "stochastic" reading is 48 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 48.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $11.05 | $11.05 |
|---|---|---|
| From the 52-week high | it is 18.8% below its 52-week high (its highest price of the past year) | -18.8% |
| Above the 52-week low | it is 182.8% above its 52-week low (its lowest price of the past year) | +182.8% |
| Below the 52-week high | it is 18.8% below its highest point of the past year | 18.8% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 35 trading days ago | 35 sessions |
| All-time high | its highest closing price on record is $11.05 (set on 2026-07-06) | $11.05 |
| Given back of the 52-week move | over the past year its closes ranged ($3.38 to $10.57), and it has given back roughly a quarter of its rise from last year’s low — 22% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $5.90 to $6.13. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 22.1% |
| From the all-time high | it is 18.8% below its all-time high | -18.8% |
| Nearest price level | it is trading 22.9% above a support level at $6.92 — a price it turned at twice since 2026-03-02, most recently on 2026-03-12. Since 2024-12-13 it has 7 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -22.9% |
| All-time low | its lowest closing price on record is $2.34 (set on 2025-04-14) | $2.34 |
| Above the all-time low | it is 283.8% above its all-time low | +283.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 60th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.5248 between its high and its low — about 5.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.5248 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $7.56 and $9.90 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $7.56 – $8.73 – $9.90 |
| Typical daily range (% of price) | its price moves about 5.8% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.8% |
| Stretch from the 200-day average | it is trading 4.8 daily ranges above its 200-day average price (39.4% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.8 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.62× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 1.7% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.7% |
|---|---|---|
| Gap filled | a 2.7% gap down opened on 2026-07-29 has been "filled" 17 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 17 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -8.65% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 3.4 percentage points (the stock gained 5.8% while the market gained 2.3%) | +3.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 3.3 percentage points (the stock lost 0.2% while the market gained 3.1%) | -3.3% |
| vs market, 6 months | over the past 6 months this stock beat the market by 47.0 percentage points (the stock gained 58.1% while the market gained 11.1%) | +47.0% |
| vs market, 12 months | over the past 12 months this stock beat the market by 114.6 percentage points (the stock gained 135.1% while the market gained 20.5%) | +114.6% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 15.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 23% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $7.29 — a volume-weighted average of daily closes over 150 sessions, not a true tick-by-tick VWAP. | +23.2% |
|---|
Price levels it has turned at before
AVR last closed at $8.98 on 2026-08-21. Since 2024-12-13 it has turned at 7 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $6.92 | Support | 22.9% below the last close | turned there twice · 2026-03-02 to 2026-03-12 |
| $6.77 | Support | 24.6% below the last close | turned there twice · 2025-02-28 to 2026-01-22 |
| $6.44 | Support | 28.3% below the last close | turned there three times · 2025-09-16 to 2026-04-14 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five.
This labelling fails — stops being a possible reading at all — if it closes below $7.72.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $8.63 and $10.09 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke out to a new 20-day high · beating the market · Trading inside the Ichimoku cloud · Elliott wave 5 candidates | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 3 analysts
- Mean price target$15.33 range $15.00 – $16.00; median $15.00
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AVR
- Consensus EPS estimate-$0.2067 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical and regulatory risk: the company is unprofitable and dependent on successful completion of the PARADIGM pivotal trial; failure to achieve primary endpoints could delay or prevent FDA approval and commercialization","Competitive market risk: established TAVR players (Edwards Lifesciences, Medtronic) and emerging competitors dominate the market; DurAVR® has limited clinical data and only 130 patients implanted to date versus thousands for competitors","Capital requirement risk: with minimal net sales ($494K in Q1 2026) and negative net margins, the company requires ongoing funding to support R&D and clinical trials; inability to raise capital could impair operations"]
What changed in the latest 10-Q
AI-assisted comparison of AVR's 10-Q filed 2026-05-12 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to annual report for year ended December 31, 2025, filed February 26, 2026 (newer filing)
- Statement that PARADIGM Trial recruitment commenced in Europe in October 2025, followed by FDA IDE approval in November 2025
- Statement that in April 2026, company secured U.S. Medicare reimbursement eligibility for PARADIGM Trial under CMS national coverage policy 20.32
- Statement that initial U.S. sites were activated with first patients enrolled and treated during May 2026
- Statement that PARADIGM Trial is supported by early clinical experience from over 130 patients treated
- Description of January 2026 underwritten public offering of 40,000,000 shares at $5.75 per share generating gross proceeds of approximately $320.0 million
- Description of stock purchase agreement with Medtronic subsidiary for 15,652,173 shares at $5.75 per share
- Statement that Transition Services Agreement with LeMaitre expired in January 2025
- Removed:
- Reference to annual report for year ended December 31, 2024, filed March 12, 2025, and amended April 29, 2025 (older filing)
- Statement that as of September 2025, a total of 130 patients have been treated with DurAVR THV worldwide
- Description of December 12, 2024 IPO with 14,800,000 shares at $6.00 per share
- Description of January 14, 2025 over-allotment option exercise for 78,481 shares at $6.00 per share
- Statement about net proceeds of $80.0 million from IPO and over-allotment
- Detailed narrative about third quarter 2025 regulatory activities in Europe, Denmark clearance, and FDA engagement
- Description of site and operational readiness activities including investigator training and logistical setup
- Statement referencing anticipation of subjects with broad array of risk profiles
- Description of operational infrastructure strengthening, QMS buildout, and ISO 13485 certification efforts
- Description of manufacturing scale-up activities in third quarter 2025
- Statement about private placement during October and November 2025 generating $25.2 million gross proceeds
- Reference to Anteris Technologies Pty Ltd (ATPL) and reorganization transactions prior to IPO
- Reworded:
- Changed 'narrowing of the aortic valve' to 'a narrowing of the aortic valve'
- Changed 'balloon expandable ComASUR ® Delivery System' to 'our ComASUR ® balloon-expandable delivery system (the "ComASUR ® Delivery System")'
- Changed 'et. al.' to 'et al.'
- Changed description of ComASUR from 'balloon expandable ComASUR ® Delivery System' to specify 'ComASUR ® balloon-expandable delivery system'
- Changed primary endpoint language from '1-year post-procedure' to 'one year post-procedure'
- Changed 'We anticipate that the subjects will include' language removed entirely in newer version
- Changed 'the Premarket Approval' to 'Premarket Approval' (removed 'the')
- Notes:
- The older filing text appears to be truncated at the end of the 'Principles of Consolidation' section, limiting ability to assess full section changes
- The newer filing text also appears truncated in the 'Revenue and Other Income' section, limiting complete comparison of later sections
Risk Factors
- Added:
- Newer filing (2026-05-12) heading title changed from 'SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS' to 'CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS'
- Newer filing reorders bullet points in forward-looking statements list with 'our R&D expenses' moved to later position
- Newer filing added reference to 'Section 27A of the Securities Act of 1933, as amended' versus older filing reference to 'Section 27A of the Securities Act'
- Newer filing updates Form 10-K reference year from December 31, 2024 to December 31, 2025 with new filing date of February 26, 2026
- Newer filing financial statements present three months ended March 31 data for 2026 vs 2025
- Newer filing cash position shows 283,210 thousand at March 31, 2026 versus 12,576 thousand at December 31, 2025
- Removed:
- Older filing (2025-11-12) presented three months and nine months ended September 30 comparative data
- Older filing Form 10-K reference dated March 12, 2025 and amended April 29, 2025 removed
- Older filing cash position data for September 30, 2025 and December 31, 2024 removed
- Reworded:
- Forward-looking statements section heading changed from 'SPECIAL NOTE' to 'CAUTIONARY NOTE' (filed 2026-05-12)
- Reordered bullet points in forward-looking statements: moved 'sufficiency of our capital resources' and 'our ability to raise additional funding' from top of list to end of list (filed 2026-05-12)
- Updated Form 10-K annual report reference from year ended December 31, 2024 filed March 12, 2025 to year ended December 31, 2025 filed February 26, 2026 (filed 2026-05-12)
- Securities Act reference expanded from 'Section 27A of the Securities Act' to 'Section 27A of the Securities Act of 1933, as amended' (filed 2026-05-12)
- Notes:
- Financial statements present different reporting periods: Q1 2026 vs 2025 in newer filing versus Q3 and nine-month 2025 vs 2024 in older filing, making direct financial comparison not assessable
- Balance sheet dates differ: March 31, 2026 versus September 30, 2025 and December 31, 2024 in older filing
- Older filing text provided was truncated and incomplete (balance sheet cuts off mid-row)
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
1 open-market purchase and 12 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 11 sells ($25M) — 1 selling insider
- Last 90 days1 buy ($102229) · 12 sells ($25M) — 1 buying, 1 selling insiders
- Last 180 days1 buy ($102229) · 12 sells ($25M) — 1 buying, 1 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-11. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AVR's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding AVR as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 9,042,431
- Reported value $50,185,493
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 3 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
AVR had 7,141,146 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
AVR had 7.33% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.93 days to cover at the same settlement.
- Reported short interest (shares) 7,141,146
- Short interest (% of shares outstanding) 7.33%
- Prior settlement (shares) 8,071,451
- Reported change -11.53%
- Days to cover (reported) 6.93
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AVR vs…
Frequently asked questions
What does ANTERIS TECHNOLOGIES GLOBAL CORP (AVR) do?
Anteris Technologies Global Corp is a structural heart company developing transcatheter aortic valve replacement (TAVR) therapies for aortic stenosis. The company's lead product, the DurAVR® THV System, is a single-piece biomimetic valve utilizing proprietary ADAPT® tissue-enhancing technology designed to mimic the performance of a healthy human aortic valve and deployed via the ComASUR® Delivery System.
What sector is ANTERIS TECHNOLOGIES GLOBAL CORP (AVR) in?
ANTERIS TECHNOLOGIES GLOBAL CORP (AVR) is classified in the Health Care sector. Its industry is Transcatheter Heart Valve Replacement Devices. It trades on NASDAQ.
Who are ANTERIS TECHNOLOGIES GLOBAL CORP's (AVR) competitors?
Notable peers of ANTERIS TECHNOLOGIES GLOBAL CORP (AVR) include Edwards Lifesciences, Medtronic, Boston Scientific and Abbott Laboratories. This peer set is informational only — not financial advice.
Is ANTERIS TECHNOLOGIES GLOBAL CORP (AVR) overbought or oversold right now?
ANTERIS TECHNOLOGIES GLOBAL CORP (AVR) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 51, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AVR come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.